TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 146.04% | -49.41% | 357.05% | 713.46% | 54,863.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.04% | -49.41% | 357.05% | 713.46% | 54,863.75% |
| Cost of Revenue | 96.07% | 166.20% | 334.54% | 534.89% | 261,700.00% |
| Gross Profit | 156.90% | -54.08% | 360.09% | 735.49% | 46,805.19% |
| SG&A Expenses | 25.07% | 28.07% | 26.29% | 23.20% | 38.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.58% | 40.00% | 6.42% | 62.39% | 8.27% |
| Operating Income | 339.88% | -89.17% | 119.73% | 74.94% | 76.02% |
| Income Before Tax | 281.47% | -96.25% | 113.76% | 72.78% | 73.53% |
| Income Tax Expenses | 444.10% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 261.84% | -96.59% | 114.45% | 72.71% | 72.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 261.84% | -96.59% | 114.45% | 72.71% | 72.80% |
| EBIT | 339.88% | -89.17% | 119.73% | 74.94% | 76.02% |
| EBITDA | 340.68% | -89.16% | 119.79% | 74.97% | 76.06% |
| EPS Basic | 259.48% | -96.65% | 114.12% | 73.82% | 73.95% |
| Normalized Basic EPS | 278.63% | -96.31% | 113.46% | 73.91% | 74.63% |
| EPS Diluted | 248.76% | -97.26% | 111.76% | 73.82% | 73.95% |
| Normalized Diluted EPS | 261.99% | -96.37% | 112.22% | 73.91% | 74.63% |
| Average Basic Shares Outstanding | 1.50% | 1.56% | 2.28% | 4.20% | 4.36% |
| Average Diluted Shares Outstanding | 11.99% | 3.11% | 12.66% | 4.20% | 4.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
